Shulman Joseph

Shulman Joseph, Chief Technical Officer at Rhythm Pharmaceuticals (RYTM), has demonstrated a clear selling bias in recent insider transactions, with $6.94 million in total sales compared to $1.52 million in purchases across 28 reported trades. The activity has been exclusively concentrated in RYTM shares, with no transactions in other companies. Joseph’s most significant sales occurred on September 2, 2025 ($1.77 million), October 30, 2025 ($1.12 million), and October 16, 2025 ($933,645 and $384,907), while smaller dispositions were recorded throughout August, September, and October 2025. The most recent transactions, filed on February 1, 2026, included a $709,197 derivative disposition (code F) alongside several smaller transactions with no reported value (code M). Notably, Joseph has not executed any open-market purchases in recent filings, with all recent activity involving sales or derivative transactions. The pattern suggests ongoing divestment, particularly in late 2025, with the pace slowing in early 2026. The transactions include a mix of outright sales (code S) and derivative dispositions (codes M and F), with the latter often representing option exercises or other equity-based compensation events. While the sales are substantial, the lack of buying activity since at least August 2025 indicates a consistent reduction in exposure to RYTM shares over time. The absence of material purchases during this period reinforces the directional trend toward net divestment.